ODDO BHF Small & MIDCAP MORNING NEWS - 05/07/2024 Date Performance sin...

...

ODDO BHF Small & MIDCAP MORNING NEWS - 07/05/2024 Date Performance dep...

...

Beneteau : Strong drop in Q1 sales, as expected, due to inventory redu...

>Q1 sales down 26.9% to € 348.7m (ODDO BHF: € 384.4m est.) - The Bénéteau group reported Q1 sales down 27.1% to € 348.7m, a more pronounced decline than we expected (our estimate € 384.4m; difference -9%). By division, this slowdown in sales in Q1 is attributable to: 1/ A strong fall in boat sales of 39% to € 228.7m (ODDO BHF: € 281.3m) due to a high base of comparison (Q1 2023 boat sales: +57%) as well as inventory drawdowns at distributors. By segment, we note...

Bénéteau : CA T1 en forte baisse, comme attendu, sous l’effet des dést...

>CA T1 en baisse de 26.9% à 348.7 M€ (ODDO BHF : 384.4 M€e) - Le groupe Bénéteau publie un CA T1 en recul de 27.1% à 348.7 M€ soit un déclin plus prononcé que nous ne l’estimions (384.4 M€ estimé ; différence -9%). Par pôle d’activité, ce ralentissement des ventes au T1 s’explique par : 1/ Une forte baisse du CA Bateaux de 39% à 228.7 M€ (ODDO BHF : 281.3 M€) en raison d’un effet de base élevé (CA Bateaux T1 2023 : +57%) ainsi que du déstockage des distributeurs...

ODDO BHF Small & MIDCAP MORNING NEWS - 04/25/2024

Having flirted with the 495-point mark on Friday, which could have triggered an extension of the correction, the market has rebounded well since then. Our technical analysis highlights a configuration in which we are only at the start of a powerful rally. Target of 622 points for Stoxx 600 index (+11%) by the end of the year confirmed. Prefer banks to insurance companies in the short term. - ...

ODDO BHF Small & MIDCAP MORNING NEWS - 25/04/2024

Après avoir frôlé vendredi la barre des 495 points qui aurait pu déclencher la poursuite de la correction, le marché a ensuite bien rebondi. Notre analyse technique met en lumière une configuration où nous ne serions qu’au début d’un rallye puissant. Objectif 622 points (+11%) d’ici à la fin de l’année confirmé sur le Stoxx 600. Préférer les banques aux assurances à court terme. - ...

Cosmo Pharmaceuticals : Change of management

>Giovanni Di Napoli to be group CEO - Cosmo Pharmaceuticals this morning announced the appointment of Giovanni Di Napoli as CEO, to replace Alessandro Della Chà. The appointment takes effect at the AGM scheduled for 24 May. This appointment follows the Capital Market Day in March which set out the next stages for the company and its ambitions. Mr Di Napoli is very familiar with the GI Genius platform, coming from Medtronic where he occupied several management pos...

Cosmo Pharmaceuticals : Changement de management

>Mr Di Napoli devient CEO du groupe - Cosmo Pharmaceuticals annonce ce matin la nomination de Giovanni Di Napoli au poste de CEO, en remplacement d’Alessandro Della Chà. Cette nomination sera effective lors de l’AGM prévu le 24 mai prochain. Cette nomination fait suite à son Capital Market Day réalisé en mars dernier exposant les prochaines étapes de la société et ses ambitions. Mr Di Napoli connait bien la plateforme GI Genius car vient de Medtronic où il a occ...

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is...

INVEST SECURITIES - OSE IMMUNO : Upfront de 48m$ confirmé, Ph III Tedo...

OSE Immunotherapeutics - Funding accelerates Tedopi clinical developme...

Despite the challenging macroeconomic environment, OSE announced an encouraging funding win with the receipt of €8.4m in non-dilutive public funding from Bpifrance (a French public sector financing institution). Proceeds will be directed to support the upcoming registrational Phase III study of lead asset Tedopi, in second-line treatment in HLA-A2 positive non-small cell lung cancer (NSCLC) patients with secondary (acquired) resistance to anti-PD-(L)1 immunotherapy. This announcement follows the...

Beneteau: 1 director

A director at Beneteau sold 3,000 shares at 13.536EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

ODDO BHF Small & MIDCAP MORNING NEWS - 04/11/2024

Waga Energy offers an innovative start-up profile in the utilities sector: i/ disruptive technology in biogas treatment, ii/ established competitive advantages, iii/ positioning on a market with strong potential (>20,000 landfills) and iv/ a robust business model based on recurring revenues. At its CMD in February 2024, the company reconfirmed its ambitions for 2026 set out at the IPO (contracts for 4 TWh and recurring revenues of € 200m). The financing secured in Q1 2024 (€ 112m base...

ODDO BHF Small & MIDCAP MORNING NEWS - 11/04/2024

Waga Energy propose un profil de start-up innovante dans le secteur des utilities : i/ une technologie disruptive pour le traitement du biogaz, ii/ des avantages compétitifs établis, iii/ un positionnement sur un marché à fort potentiel (>20 000 décharges) et iv/ un modèle robuste de revenus récurrents. La société a reconfirmé lors du CMD en février 2024 ses ambitions à horizon 2026 annoncées au moment de son IPO (signature de 4 TWh et CA récurrent de 200 M€). Fort des financements ob...

OSE Immunotherapeutics : Public financing of € 8m to support the devel...

>A first step for the financing of phase III registration - Yesterday, OSE Immunotherapeutics announced that it was to receive public funds of up to € 8.4m to support the phase III clinical study for the registration of Tedopi in 2L for the treatment of non-small cell lung cancer (NSCLC), for HLA-A2 positive patients with secondary or acquired anti-PD(L)1 resistance. This non-dilutive financing come on foot of the call for “ i-Démo” projects as part of Bpifrance's Fra...

OSE Immunotherapeutics : Financement public de 8 M€ pour soutenir le d...

>Une première étape pour le financement de la phase 3 d’enregistrement - OSE Immunotherapeutics a annoncé hier qu’elle recevait un financement public à hauteur de 8.4 M€ pour soutenir l’essai clinique de phase 3 d’enregistrement de Tedopi en 2L de traitement dans le cancer du poumon non à petites cellules (NSCLC), chez des patients HLA-A2 positifs, en résistance secondaire ou acquise aux anti-PD(L)1. Ce financement non dilutif fait suite à l’appel à projets « i-Démo ...